Clinical Trial Update: Safety Study of an Intravenous Staphylococcus Aureus Immune Globulin (Human), [Altastaph] in Low-Birth-Weight-Neonates [Phase 2]

View source ↗

Summary

Phase 2 safety study of Altastaph, intravenous Staphylococcus aureus immune globulin (human), in low-birth-weight neonates has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Staphylococcal Infections

Drugs mentioned

• Altastaph (Staphylococcus aureus immune globulin intravenous (Human))

Snippet

Sponsor: Nabi Biopharmaceuticals | Conditions: Staphylococcal Infections | Phase 2 | Status: COMPLETED